AstraZeneca Plc's AZN supplemental New Drug Application for Tagrisso (osimertinib) in combination with chemotherapy has been accepted and granted Priority Review in the U.S. for locally advanced or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results